Syndax Pharmaceuticals, Inc. (“Syndax” or the “Company”) (NASDAQ: SNDX) is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company’s two lead product candidates are revumenib (SNDX-5613) and axatilimab (SNDX-6352). Syndax is developing revumenib, a selective, small molecule inhibitor of the menin-MLL binding interaction, for the treatment of mixed lineage leukemia, acute Leukemias, and nucleophosmin 1. The Company is developing axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor, for the treatment of chronic graft-versus-host disease, as well as idiopathic pulmonary fibrosis.